JP2010528047A5 - - Google Patents

Download PDF

Info

Publication number
JP2010528047A5
JP2010528047A5 JP2010509554A JP2010509554A JP2010528047A5 JP 2010528047 A5 JP2010528047 A5 JP 2010528047A5 JP 2010509554 A JP2010509554 A JP 2010509554A JP 2010509554 A JP2010509554 A JP 2010509554A JP 2010528047 A5 JP2010528047 A5 JP 2010528047A5
Authority
JP
Japan
Prior art keywords
composition
antibody
factor
antagonist
amd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010509554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528047A (ja
JP5416695B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/064526 external-priority patent/WO2008147883A1/en
Publication of JP2010528047A publication Critical patent/JP2010528047A/ja
Publication of JP2010528047A5 publication Critical patent/JP2010528047A5/ja
Application granted granted Critical
Publication of JP5416695B2 publication Critical patent/JP5416695B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010509554A 2007-05-23 2008-05-22 補体が関係している眼の状態の予防および治療 Expired - Fee Related JP5416695B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
US60/939,791 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013236445A Division JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療

Publications (3)

Publication Number Publication Date
JP2010528047A JP2010528047A (ja) 2010-08-19
JP2010528047A5 true JP2010528047A5 (cg-RX-API-DMAC7.html) 2012-05-10
JP5416695B2 JP5416695B2 (ja) 2014-02-12

Family

ID=39638868

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010509554A Expired - Fee Related JP5416695B2 (ja) 2007-05-23 2008-05-22 補体が関係している眼の状態の予防および治療
JP2013236445A Withdrawn JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療
JP2016015288A Withdrawn JP2016145205A (ja) 2007-05-23 2016-01-29 補体が関係している眼の状態の予防および治療
JP2017146477A Pending JP2017197577A (ja) 2007-05-23 2017-07-28 補体が関係している眼の状態の予防および治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013236445A Withdrawn JP2014087346A (ja) 2007-05-23 2013-11-15 補体が関係している眼の状態の予防および治療
JP2016015288A Withdrawn JP2016145205A (ja) 2007-05-23 2016-01-29 補体が関係している眼の状態の予防および治療
JP2017146477A Pending JP2017197577A (ja) 2007-05-23 2017-07-28 補体が関係している眼の状態の予防および治療

Country Status (28)

Country Link
US (6) US8007791B2 (cg-RX-API-DMAC7.html)
EP (1) EP2152755B1 (cg-RX-API-DMAC7.html)
JP (4) JP5416695B2 (cg-RX-API-DMAC7.html)
KR (1) KR101540126B1 (cg-RX-API-DMAC7.html)
CN (3) CN107096029B (cg-RX-API-DMAC7.html)
AR (1) AR066660A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008256835B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0811142A8 (cg-RX-API-DMAC7.html)
CA (1) CA2683498A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008001498A1 (cg-RX-API-DMAC7.html)
CY (1) CY1116062T1 (cg-RX-API-DMAC7.html)
DK (1) DK2152755T3 (cg-RX-API-DMAC7.html)
ES (1) ES2533242T3 (cg-RX-API-DMAC7.html)
HK (1) HK1207327A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150281T1 (cg-RX-API-DMAC7.html)
IL (2) IL201476A (cg-RX-API-DMAC7.html)
MX (1) MX2009012422A (cg-RX-API-DMAC7.html)
PE (1) PE20090294A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500992B1 (cg-RX-API-DMAC7.html)
PL (1) PL2152755T3 (cg-RX-API-DMAC7.html)
PT (1) PT2152755E (cg-RX-API-DMAC7.html)
RS (1) RS53901B1 (cg-RX-API-DMAC7.html)
RU (2) RU2522976C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201401404RA (cg-RX-API-DMAC7.html)
SI (1) SI2152755T1 (cg-RX-API-DMAC7.html)
TW (2) TW201417829A (cg-RX-API-DMAC7.html)
WO (1) WO2008147883A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907028B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316446T3 (es) * 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
JP2010508819A (ja) 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CA2735779A1 (en) * 2008-09-02 2010-03-11 Matthew Burger Bicyclic kinase inhibitors
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
US9492315B2 (en) * 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
MX348025B (es) 2010-11-01 2017-05-24 Genentech Inc * Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
PH12013501436A1 (en) 2011-01-04 2013-09-09 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104684910B (zh) 2012-07-12 2016-10-12 诺华股份有限公司 补体途经调节剂及其用途
DK2877493T3 (en) 2012-07-25 2018-06-14 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015054298A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
WO2015061658A1 (en) * 2013-10-25 2015-04-30 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
JP2017515811A (ja) * 2014-05-01 2017-06-15 ジェネンテック, インコーポレイテッド 抗d因子抗体変異体及びその使用法
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
RS66924B1 (sr) * 2015-09-23 2025-07-31 Sangamo Therapeutics Inc Htt represori i njihova upotreba
CN108289951A (zh) * 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3368578B1 (en) 2015-10-30 2021-03-17 H. Hoffnabb-La Roche Ag Anti-htra1 antibodies and methods of use thereof
CN108472382A (zh) * 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
HK1257425A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
SI3394089T1 (sl) * 2015-12-23 2021-12-31 eleva GmbH Polipeptidi za inhibiranje aktivacije komplementa
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
IL268601B2 (en) 2017-02-10 2024-07-01 Univ Pennsylvania Anti-factor d antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009778A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods for culturing mesenchymal stem cells, products thereof, and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2001036432A2 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 18 human secreted proteins
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) * 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2316175T3 (es) 1997-11-21 2009-04-01 Genentech, Inc. Antigenos especificos de plaquetas y sus usos farmacologicos.
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2577799A (en) * 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
CA2321140C (en) * 1998-02-20 2015-04-07 Tanox, Inc. Inhibitors of complement activation
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
JP2002523089A (ja) 1998-08-27 2002-07-30 インサイト・ファーマスーティカルズ・インコーポレイテッド タンパク質輸送関連分子
CA2348757A1 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2259247T3 (es) * 1998-12-21 2006-09-16 Ludwig Institute For Cancer Research Anticuerpos frente a vegf-d truncado y sus usos.
ATE353339T1 (de) 1998-12-22 2007-02-15 Genentech Inc Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums
EP1220905A2 (en) 1999-03-08 2002-07-10 Genentech Inc. Composition and methods for the treatment of immune related diseases
HU229376B1 (en) 1999-03-11 2013-11-28 Serono Lab Vascular adhesion molecules and modulation of their function
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1423601A (en) 1999-11-02 2001-05-30 Uliyanovsky Gosudarstvenny Tekhnichesky Universitet Method for cleaning liquids of ferromagnetic particles and device for the implementation thereof
CA2494705A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
NZ567483A (en) * 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
JP2010508819A (ja) * 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Similar Documents

Publication Publication Date Title
JP2010528047A5 (cg-RX-API-DMAC7.html)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
AU2025271125A1 (en) Methods for treating or preventing ophthalmological conditions
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2011504872A5 (cg-RX-API-DMAC7.html)
JP5990511B2 (ja) 血管新生に基づく眼障害の処置のための抗cd160特異的抗体
JP2016504416A5 (cg-RX-API-DMAC7.html)
US20220162296A1 (en) Personalized treatment of ophthalmologic diseases
JP2020535184A5 (cg-RX-API-DMAC7.html)
RU2008144802A (ru) Применение антител против ил-1 для лечения глазных расстройств
RU2015121755A (ru) Антагонисты ил-6 и их применение
JP2017535285A5 (cg-RX-API-DMAC7.html)
JP2015503909A5 (cg-RX-API-DMAC7.html)
EP2200699A1 (en) Antigen binding proteins
JP2011503094A5 (cg-RX-API-DMAC7.html)
JP2017502023A (ja) 眼疾患を治療する組成物および方法
JP2018530574A5 (cg-RX-API-DMAC7.html)
RU2018103960A (ru) Антитела против ang-2, содержащие только тяжелую цепь
JP2018527327A5 (cg-RX-API-DMAC7.html)
JP2025114621A (ja) 神経変性疾患を治療するための改変抗pd-l1抗体および治療方法および使用
JP2018523673A5 (cg-RX-API-DMAC7.html)
JP7382343B2 (ja) Mfap4に対する抗体
JP2021513360A5 (cg-RX-API-DMAC7.html)
JP2020518641A5 (cg-RX-API-DMAC7.html)
RU2022102753A (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ